(Q50534602)

14 March 2018

title

Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes (English)

1 reference

14 March 2018

author

Yukio Kobayashi

3

1 reference

14 March 2018

Kazuma Ohyashiki

12

object named as

Kazuma Ohyashiki

1 reference

14 March 2018

16

Kensei Tobinai

1 reference

14 March 2018

Noriko Usui

7

object named as

Noriko Usui

1 reference

14 March 2018

author name string

Toshiki Uchida

1

1 reference

14 March 2018

Yoshiaki Ogawa

2

1 reference

14 March 2018

Takayuki Ishikawa

4

1 reference

14 March 2018

Haruhiko Ohashi

5

1 reference

14 March 2018

Tomoko Hata

6

1 reference

14 March 2018

Masafumi Taniwaki

8

1 reference

14 March 2018

Kazunori Ohnishi

9

1 reference

14 March 2018

Hideki Akiyama

10

1 reference

14 March 2018

Keiya Ozawa

11

1 reference

14 March 2018

Shinichiro Okamoto

13

1 reference

14 March 2018

Akihiro Tomita

14

1 reference

14 March 2018

Shinji Nakao

15

1 reference

14 March 2018

Michinori Ogura

17

1 reference

14 March 2018

Kiyoshi Ando

18

1 reference

14 March 2018

Tomomitsu Hotta

19

1 reference

14 March 2018

publication date

12 July 2011

1 reference

14 March 2018

published in

Cancer Science

1 reference

14 March 2018

volume

102

1 reference

14 March 2018

issue

9

1 reference

14 March 2018

page(s)

1680-1686

1 reference

14 March 2018

Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS).

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01993.X

Proposals for the classification of the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01993.X

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01993.X

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01993.X

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01993.X

Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01993.X

Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01993.X

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01993.X

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01993.X

10.1111/J.1349-7006.2011.01993.X

21 January 2018

Identifiers

DOI

1 reference

14 March 2018

1 reference

14 March 2018